colistin
Jump to navigation
Jump to search
Introduction
A mixture of cyclic polypeptide antibiotics derived from a strain of Bacillus polymyxa.
It consists primarily of colistin A with small amounts of colistin B.
Indications
- drug-resistant, gram-negative nosocomial infection
- Acinetobacter baumannii[2]
- carbapenem-resistant bacteria[7]
- ventilator-associated pneumonia[2][3]
Dosage
Monitor
Adverse effects
- nephrotoxicity (50%) generally reversible[4]
- neurotoxicity
- neruomuscular blockade
Laboratory
Notes
- report of colistin-resistant E coli in the U.S.
- transmission to contacts uncommon[10]
- mcr-1 testing of all Enterobacteriaceae isolates with a colistin or polymyxin B minimum inhibitory concentration of 4 ug/mL or higher[10]
- testing can be performed through the CDC
More general terms
More specific terms
Component of
References
- ↑ Stedman's Medical Dictionary 27th ed, Williams & Wilkins, Baltimore, 1999
- ↑ 2.0 2.1 2.2 Journal Watch 23(13):104, 2003 Garnacho-Montero J et al Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Inect Dis 36:1111, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12715304
- ↑ 3.0 3.1 Florescu DF et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22322268
Falagas ME and Rafailidis PI. Colistin in ventilator-associated pneumonia. Clin Infect Dis 2012 Mar 1; 54:681. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22322269 - ↑ 4.0 4.1 4.2 4.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19. American College of Physicians, Philadelphia 2012, 2015, 2018, 2021.
- ↑ Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15825037 Free Article
- ↑ 6.0 6.1 Rosen M Bacteria resistant to last-resort antibiotic appears in U.S. Science News. May 27, 2016 https://www.sciencenews.org/article/bacteria-resistant-last-resort-antibiotic-appears-us
McGann P et al. Escherichia coli harboring mcr-1and bla(CTX-M) on a novel IncF plasmid: First report of mcr-1in the USA. Antimicrobial Agents and Chemotherapy. May 26, 2016 http://aac.asm.org/content/early/2016/05/25/AAC.01103-16 - ↑ 7.0 7.1 7.2 7.3 Orciari Herman A, Fairchild DG Bacteria Resistant to Last-Resort Antibiotic Discovered in U.S. Physician's First Watch, May 31, 2016 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
- ↑ 8.0 8.1 Kline KE, Shover J, Kallen AJ, Lonsway DR, Watkins S, Miller JR. Investigation of First Identified mcr-1 Gene in an Isolate from a U.S. Patient - Pennsylvania, 2016. MMWR Morb Mortal Wkly Rep. ePub: 9 September 2016 http://www.cdc.gov/mmwr/volumes/65/wr/mm6536e2.htm
- ↑ 9.0 9.1 Vasquez AM, Montero N, Laughlin M, et al. Investigation of Escherichia coli Harboring the mcr-1 Resistance Gene - Connecticut, 2016. MMWR Morb Mortal Wkly Rep. ePub: 9 September 2016 http://www.cdc.gov/mmwr/volumes/65/wr/mm6536e3.htm
- ↑ 10.0 10.1 10.2 Orciari Herman A, Sadoughi S, Sofair A. CDC: E. Coli Resistant to Last-Resort Antibiotic Again Found in U.S., No Transmission Seen Physician's First Watch, Sept 12, 2016 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org